LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Home・Aktien・Cassava Sciences Inc

Cassava Sciences Inc

Geschlossen

BrancheGesundheitswesen

3.27 -3.82

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.25

Max

3.32

Schlüsselkennzahlen
By Trading Economics
Einkommen	33M -11M
Verkäufe	840K 840K
EPS	-0.22
Gewinnspanne	-1,286.548
Angestellte	30
EBITDA	35M -11M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+135.99% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-4.3M 142M
Vorheriger Eröffnungskurs	7.09
Vorheriger Schlusskurs	3.27

Nachrichtenstimmung

By Acuity

46%

54%

155 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

1.56 / 1.7 Unterstützung & Widerstand

Cassava Sciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

28. Nov. 2025, 15:29 UTC

Wichtige Markttreiber

Akquisitionen, Fusionen, Übernahmen

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

28. Nov. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28. Nov. 2025, 19:59 UTC

Market Talk

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

28. Nov. 2025, 19:47 UTC

Market Talk

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

28. Nov. 2025, 18:16 UTC

Market Talk

Global Equities Roundup: Market Talk

28. Nov. 2025, 18:16 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28. Nov. 2025, 18:08 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

28. Nov. 2025, 18:08 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28. Nov. 2025, 17:48 UTC

Market Talk

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

28. Nov. 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28. Nov. 2025, 16:50 UTC

Akquisitionen, Fusionen, Übernahmen

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

28. Nov. 2025, 15:51 UTC

Market Talk

Canada Household Spending Edges Lower -- Market Talk

28. Nov. 2025, 15:33 UTC

Market Talk

Crude Futures Gain as U.S. Market Reopens -- Market Talk

28. Nov. 2025, 15:21 UTC

Market Talk

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

28. Nov. 2025, 15:13 UTC

Market Talk

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

28. Nov. 2025, 15:11 UTC

Market Talk

Global Equities Roundup: Market Talk

28. Nov. 2025, 15:11 UTC

Market Talk

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

28. Nov. 2025, 14:51 UTC

Market Talk

Canada GDP Report Masks Fragile State of Economy -- Market Talk

28. Nov. 2025, 14:41 UTC

Market Talk

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

28. Nov. 2025, 14:37 UTC

Market Talk

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

28. Nov. 2025, 14:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. Nov. 2025, 14:33 UTC

Market Talk

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

28. Nov. 2025, 14:20 UTC

Market Talk

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

28. Nov. 2025, 14:10 UTC

Market Talk

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

28. Nov. 2025, 13:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. Nov. 2025, 13:39 UTC

Market Talk

Canada Trade Data Could Face Larger-Than-Normal Revisions -- Market Talk

28. Nov. 2025, 13:36 UTC

Market Talk

Canada's Economy Expands More Than Expected -- Market Talk

28. Nov. 2025, 13:29 UTC

Market Talk

CME Outage Sowing Chaos Across Markets, Trade Nations Says -- Market Talk

28. Nov. 2025, 13:27 UTC

Market Talk

Russia-Ukraine Peace Efforts to Have Little Impact on Oil Fundamentals -- Market Talk

28. Nov. 2025, 13:19 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Cassava Sciences Inc Prognose

Kursziel

By TipRanks

135.99% Vorteil

12-Monats-Prognose

Durchschnitt 8 USD 135.99%

Hoch 8 USD

Tief 8 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cassava Sciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cassava Sciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.56 / 1.7Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Stimmung

By Acuity

155 / 374 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.